Arcturus Therapeutics (ARCT) Misses Q1 EPS by 411c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of ($0.52), $4.11 worse than the analyst estimate of $3.59. Revenue for the quarter came in at $29.38 million versus the consensus estimate of $205.21 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• OBOOK Holdings posts $18.8M net loss as OwlPay Harbor volume rises
• Lazard Global Total Return fund declares $0.1534 monthly distribution